A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …
AstraZeneca’s oncology pipeline has suffered a further blow after prostate cancer drug zibotentan failed to meet its primary endpoint of …

